Birth Control & Depression: Evidence Review by Contraceptive Method

The relationship between hormonal contraception and mood is complex. Large population studies show small absolute risks but important individual variation. Here’s what the evidence says.

Key Epidemiological Findings

• Danish Registry Study (Skjøth et al., JAMA Psychiatry 2018): 1M+ women, 13 years. Current/recent CHC use: RR 1.23 (95% CI 1.22–1.25) for first depression diagnosis; RR 1.34 for first antidepressant use. Highest in adolescents (15–19: RR 1.8).
• Absolute Risk: ~2.2% per year on CHC vs. ~1.7% non‑users (number needed to harm ~200).
• Progestin‑Only Methods: Mixed data. Some studies show no increase; others show similar elevation (especially DMPA).
• IUDs (Hormonal): Most studies show no increased risk; some suggest protective effect vs. non‑users.
• Implant: Limited data; generally reassuring.

Method‑Specific Evidence

Combined Oral Contraceptives (COCs)

• Risk Factors for Depression: Adolescence, history of depression, PMDD, postpartum depression, high‑dose estrogen (≥30 µg EE), certain progestins (levonorgestrel, norethindrone > desogestrel, drospirenone).
• Protective Factors: Lower estrogen (10–20 µg), anti‑androgenic progestins (drospirenone, dienogest), continuous/extended regimens.
• Mechanism: Estrogen ↑ MAO (↓ serotonin); progestin ↓ allopregnanolone (neurosteroid); HPA axis modulation.

Progestin‑Only Pill (POP / Minipill)

• Traditional (norethindrone): Less mood data; likely lower risk than CHC.
• Drospirenone‑only (Slynd): Newer; anti‑androgenic; theoretical mood benefit.

DMPA Injection (Depo‑Provera)

• Most consistently associated with mood worsening in observational studies.
• High progestin dose, no estrogen, long‑acting (can’t remove).
• Consider alternative if depression history.

Hormonal IUDs (LNG‑IUS)

• Local effect predominant; serum LNG ~200 pg/mL (vs. 1000–2000 pg/mL pills).
• Multiple cohort studies: no increased depression risk; some show lower rates vs. non‑users.
• Possible mechanisms: avoids first‑pass hepatic metabolism; minimal neurosteroid disruption.

Contraceptive Implant (ENG)

• Serum ENG levels moderate (steady).
• Limited prospective data; existing studies reassuring.
• Bleeding changes may indirectly affect mood.

Copper IUD

• No hormones → no direct neuroendocrine effect.
• Some studies show lower depression rates vs. hormonal methods (confounding: healthier user bias?).

Vaginal Ring / Patch

• Ring: Lower EE, no first‑pass → theoretical advantage.
• Patch (Xulane): Higher EE exposure → potential for more mood effects.

Clinical Approach

1. Screen: PHQ‑2/9 at initiation and follow‑up.
2. History: Prior depression, PMDD, postpartum depression, family history.
3. Counsel: Small absolute risk; most women do not develop depression; reversible.
4. Method Selection:
   • Depression history → consider Copper IUD, Hormonal IUD, Implant, POP.
   • Adolescent → extra counseling; consider non‑daily methods.
   • PMDD → Drospirenone COC or continuous regimen may help.
5. Monitor: 3‑month follow‑up; switch method if mood worsens.
6. Don’t Attribute All Mood Changes to Contraception: Life stressors, circadian disruption, relationship changes.

Emergency Contraception & Mood

• Ulipristal (Ella) / LNG (Plan B): Transient mood symptoms reported (anxiety, irritability) but no evidence of clinical depression.
• Copper IUD for EC: No mood effects.

Research Gaps

• RCTs with mood primary outcome (ethically challenging).
• Progestin‑specific effects (androgenic vs. anti‑androgenic).
• Genetic polymorphisms (CYP, BDNF, serotonin transporter).
• Long‑term neurodevelopmental effects (adolescent initiation).

Bottom Line: Hormonal contraception carries a small but real increased risk of depression diagnosis/treatment, highest in adolescents and those with prior mood disorders. Non‑hormonal and low‑systemic hormonal options (Cu‑IUD, LNG‑IUS, implant) are reasonable alternatives. Individual response is unpredictable—monitor and switch if needed.